Oculis Holding AG
OCS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953530
No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $322.0M in total; no superinvestor holds it.
Other share classesOCSAW
Q1 2024 vs. Q4 2023
How the institutions holding Oculis Holding AG changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 7 | 9 | +2 |
| Shares | 3.98M | 3.39M | −591.1K (−14.8%) |
| Value | $44.3M | $40.9M | −$3.40M (−7.7%) |
New holders (3)
Institutions that held Oculis Holding AG at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 14,944 | $180.1K | 0.00% |
| UBS Group AG | 1,097 | $13.2K | 0.00% |
| JPMorgan Chase & Co | 1 | $12 | 0.00% |
Sold out (1)
Institutions that held Oculis Holding AG at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Searle & Co. | 10,000 | $11.0K |